Literature DB >> 2462014

Monoclonal antibodies to the E1 and E2 glycoproteins of Sindbis virus: definition of epitopes and efficiency of protection from fatal encephalitis.

Q P Mendoza1, J Stanley, D E Griffin.   

Abstract

Protection of mice from fatal neuroadapted Sindbis virus encephalitis can be accomplished by passive transfer of monoclonal antibodies (MAbs) to either the E1 or E2 glycoprotein of Sindbis virus. Both neutralizing and non-neutralizing MAbs can be protective. To define further the characteristics of MAbs that provide protection from fatal disease, antigenic epitopes on the E1 and E2 glycoproteins were identified using a competitive binding enzyme immunoassay. Four distinct epitopes on E1 and three on E2 were defined. MAbs to all E1 epitopes, both neutralizing (three) and non-neutralizing (one) protected mice from fatal encephalitis. MAbs to the E2 neutralizing epitopes (two) protected mice from fatal encephalitis while those to the non-neutralizing epitope did not. The efficiency of protection from fatal Sindbis virus encephalitis of four neutralizing and non-neutralizing protective anti-E1 and anti-E2 MAbs representing different epitopes was compared. The neutralizing MAbs (against epitopes E2-ab, E2-c and E1-c) gave 50% protection at lower doses (2 to 20 micrograms) than the non-neutralizing MAb representing epitope E1-e (150 micrograms) when given before virus challenge. When given after virus challenge, MAbs to E2-ab and E2-c protected at lower doses (0.03 to 0.3 micrograms) than did either MAbs to E1-c (greater than 100 micrograms) or E1-e (10 micrograms). The MAbs to E1-e, E2-ab and E2-c were required in larger amounts to afford protection before than after challenge, while the opposite was true for MAb to E1-c.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462014     DOI: 10.1099/0022-1317-69-12-3015

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  23 in total

1.  Control of Sindbis virus infection by antibody in interferon-deficient mice.

Authors:  A P Byrnes; J E Durbin; D E Griffin
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Binding of Sindbis virus to cell surface heparan sulfate.

Authors:  A P Byrnes; D E Griffin
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

4.  Structural localization of the E3 glycoprotein in attenuated Sindbis virus mutants.

Authors:  A M Paredes; H Heidner; P Thuman-Commike; B V Prasad; R E Johnston; W Chiu
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

5.  Single-Site Glycoprotein Mutants Inhibit a Late Event in Sindbis Virus Assembly.

Authors:  Joseph Magliocca; Ricardo Vancini; Raquel Hernandez; Dennis T Brown
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

Review 6.  The alphaviruses: gene expression, replication, and evolution.

Authors:  J H Strauss; E G Strauss
Journal:  Microbiol Rev       Date:  1994-09

7.  Effects of anti-E2 monoclonal antibody on sindbis virus replication in AT3 cells expressing bcl-2.

Authors:  P Després; J W Griffin; D E Griffin
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Antiviral activity of alpha interferon in Sindbis virus-infected cells is restored by anti-E2 monoclonal antibody treatment.

Authors:  P Després; J W Griffin; D E Griffin
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Identification of a putative alphavirus receptor on mouse neural cells.

Authors:  S Ubol; D E Griffin
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Deletions in the putative cell receptor-binding domain of Sindbis virus strain MRE16 E2 glycoprotein reduce midgut infectivity in Aedes aegypti.

Authors:  Kevin M Myles; Dennis J Pierro; Ken E Olson
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.